2024-03-07 11:30:21 ET
Summary
- Galapagos has managed to curtail its R&D and G&A expenses, demonstrating efficient cost management.
- The company has strategically focused on oncology and immunology, sectors with high unmet medical needs and market impact potential.
- Galapagos is investing in CAR-T cell therapies, with promising early data indicating progress in its unique manufacturing platform.
Galapagos ( GLPG ) has been overcoming its historical financial turmoil by repositioning itself strategically and having a focused innovation pipeline. Although collaboration revenues have declined nominally and the company has suffered a net operating loss, Galapagos has managed to curtail its R&D and G&A expenses, which demonstrates efficient cost management....
Read the full article on Seeking Alpha
For further details see:
Galapagos: Pipeline Still Progressing Despite Financial Volatility